In short
Clinical trials are studying Siponimod in people with progressive multiple sclerosis, especially secondary progressive MS. These studies look at whether treatment can change imaging signs, immune markers, and disease progression, and they also measure safety and treatment effects in different patient groups.
Key points
- Siponimod is being studied in Phase 3 trials for progressive multiple sclerosis, especially secondary progressive MS. The trials focus on people with active progressive disease or secondary progressive MS. Researchers are looking at MRI changes, including paramagnetic rim lesions, and immune markers in blood and cerebrospinal fluid. One study plans to enroll 60 people, and another plans to enroll 40 people. The main goals are to see whether Siponimod changes signs of inflammation and disease activity over time.
Trial overview
Two authorised interventional trials are studying Siponimod in people with progressive multiple sclerosis. One trial focuses on the effect of treatment on paramagnetic rim lesions, which are MRI findings linked with ongoing inflammation. The other trial looks at chronic inflammation inside the nervous system by measuring markers in blood and cerebrospinal fluid.
Who the studies are for
One study includes people with an active progressive multiple sclerosis course after an initial relapse clinical course. This means the disease started with relapses, then became steadily progressive while still showing activity. The other study includes patients with secondary progressive MS.
In simple terms, these trials are not for all forms of multiple sclerosis; they focus on people whose disease has already moved into a progressive stage.
What the trials are measuring
The first trial uses MRI-based change in the susceptibility of rim lesions as its main endpoint. The researchers compare the change after Siponimod with the natural change seen before treatment in the same person, so each patient serves as their own comparison.
The second trial measures changes in cerebrospinal fluid markers of chronic intrathecal inflammation, with a special focus on CXCL13. The study description says CXCL13 is linked with B-cell accumulation and with disease severity and progression. This trial also follows paired blood and cerebrospinal fluid samples over at least two years.
Trial phases and study size
Both Siponimod studies are Phase 3 trials. Phase 3 studies are later-stage clinical trials that look at how well a treatment works in a defined patient group and continue to collect important study data.
The planned enrollment is 60 people in the MRI-focused study and 40 people in the inflammation-focused study. These are relatively small, focused studies rather than very large population trials.
How the studies are designed
Both trials are interventional, which means the researchers give a treatment and then measure what happens. The study records list Siponimod under the product name Mayzent and also under the development code BAF312 in the first trial. In the second trial, the treatment is listed as Mayzent 0.25 mg and 2 mg film-coated tablets.
The first study uses an internal comparison, meaning it compares each person’s results after treatment with their own recent pre-treatment period. The second study follows people for at least two years and looks at paired blood and spinal fluid samples over time.
Key points for patients
These trials are trying to learn whether Siponimod changes signs of disease activity in progressive multiple sclerosis. One trial looks mainly at MRI lesions, while the other looks mainly at immune markers in spinal fluid.
The target groups are people with active progressive MS and people with secondary progressive MS. Both studies are in Phase 3 and are designed to give more detailed evidence about treatment effects in these specific patient groups.